CombiGene AB (publ) announced that the company will regain the global rights for the epilepsy project CG01 from Spark Therapeutics by January 12, 2024. The collaboration agreement between CombiGene and Spark Therapeutics, which was signed in October 2021, shall be terminated because of a strategic decision by Spark Therapeutics to deprioritize the further development of CG01 in epilepsy as part of their current pipeline. The collaboration agreement signed in October 2021 gave Spark the exclusive global license to develop, manufacture and commercialize CG01.

Under the terms of the agreement, CombiGene was entitled to receive up to USD 328.5 million excluding royalties. During the collaboration, CombiGene has also been compensated for agreed development costs. CombiGene is not liable for any of the payments received by the company from Spark Therapeutics, totaling USD 8,5 million excluding development costs, but is also not entitled to any future milestone payments or royalties.